Trabectedin
- Generic Name
- Trabectedin
- Brand Names
- Yondelis
- Drug Type
- Small Molecule
- Chemical Formula
- C39H43N3O11S
- CAS Number
- 114899-77-3
- Unique Ingredient Identifier
- ID0YZQ2TCP
- Background
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machin...
- Indication
用于治疗急性淋巴母细胞白血病、晚期软组织肉瘤及复发卵巢癌。
- Associated Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Platinum Sensitive Relapsed Ovarian Cancer, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
- Associated Therapies
- -
Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-09-03
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 40
- Registration Number
- NCT00002904
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇩🇪Martin Luther Universitaet, Halle Saale, Germany
🇩🇪Universitats-Krankenhaus Eppendorf, Hamburg, Germany
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 132
- Registration Number
- NCT00003939
Ecteinascidin 743 in Treating Children With Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2014-02-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 13
- Registration Number
- NCT00006463
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸State University of New York - Upstate Medical University, Syracuse, New York, United States
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
- Conditions
- First Posted Date
- 2004-04-19
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005625
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00017030
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
- Conditions
- First Posted Date
- 2004-01-15
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- PharmaMar
- Registration Number
- NCT00027508
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer
- First Posted Date
- 2003-11-11
- Last Posted Date
- 2014-04-08
- Target Recruit Count
- 59
- Registration Number
- NCT00072670
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 50
- Registration Number
- NCT00070109
- Locations
- 🇺🇸
Childrens Memorial Hospital, Chicago, Illinois, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
A Study of Trabectedin in Patients With Advanced Ovarian Cancer
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2013-01-10
- Target Recruit Count
- 147
- Registration Number
- NCT00050414
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2013-01-08
- Target Recruit Count
- 50
- Registration Number
- NCT00050440
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.